Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02406209) enrolled 45 people across three groups to compare different eye drop treatments for eye inflammation. The three groups were: NS2 eye drops (0.5%) alone (15 people); NS2 (0.5%) combined with Pred Forte® (0.1%) eye drops (16 people); and Pred Forte® (1%) eye drops alone (14 people). Roughly half of the participants in each group completed the study — 7, 7, and 6 people respectively — while the remainder did not finish. The main thing the trial measured was a score called the "anterior chamber cell grade" — a scale from 0 to 4 that rates the level of inflammatory cells visible inside the eye, where 0 means none and 4 means severe. The reported data shows the change in this score from the start of the trial to week 8. The NS2-only group showed an average change of −0.7 units on that scale; the NS2 combined with low-dose Pred Forte® group showed a change of −0.9 units; and the standard Pred Forte® (1%) group showed a change of −0.5 units. A negative number means the score went down (i.e., moved toward fewer cells) compared to the starting point. No secondary outcome data was reported in the submitted results. It is worth noting that the relatively small number of people who completed each group makes these numbers difficult to draw broad conclusions from. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 32955967) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with non-infectious anterior uveitis (inflammation at the front of the eye that is not caused by an infection)
- The level of inflammation in the front part of your eye falls within a certain range (graded 1 to 3 by your eye doctor)
- The pressure in your study eye is below 25 mmHg at the start of the trial, and you need no more than one eye drop medication to control that pressure
- Your vision in the study eye is at least 20/200 (this means you can see at 20 feet what someone with typical vision can see at 200 feet)
Who may not be able to join:
- You have a serious or severe eye disease or condition affecting the study eye
- You currently have active inflammation in the middle or back parts of your eye
- You had a previous episode of anterior uveitis in the study eye within the 4 weeks before your first trial visit
- You have taken steroid tablets or pills by mouth within the 14 days before your first trial visit
- You have received a steroid injection into or around your study eye within the past 6 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Anterior Chamber Cell Grade at Week 8
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.